Roger S. McIntyre, MD, FRCPC, professor, Departments of Psychiatry and Pharmacology, University of Toronto, and of the Head, Mood Disorders, Psychopharmacology Unit, University Health Network, discussed the contributing factors and effects of misdiagnosing or inappropriately treating patients with antidepressants.
During a session at the 2017 Neuroscience Education Institute Congress in Colorado Springs, Colorado, Roger S. McIntyre, MD, FRCPC, professor, Departments of Psychiatry and Pharmacology, University of Toronto; Head of the Mood Disorders Psychopharmacology Unit, University Health Network, discussed the contributing factors and effects of misdiagnosing or inappropriately treating patients with antidepressants.
“We know that major depressive disorder and bipolar disorders are common conditions,” said McIntyre. “And we know still, in 2017, that the majority of people who have major depressive disorder or bipolar disorder either are not diagnosed accurately and/or are not diagnosed in a timely fashion.”
McIntyre first explained that many patients with unipolar depression that show a “little bit of mania” are more likely to have an eventual diagnostic conversion to bipolar disorder.
He then discussed how the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), the standard classification of mental disorders used by mental health professionals in the United States, is a contributing factor to the difficulty of diagnosing depression with mixed features (DMX).
“Although irritability, distractibility, and psychomotor agitation are among the most common symptoms of DMX, they are excluded from DSM-5 mixed features criteria due to the overlap of these symptoms with other disorders and between mania and depression,” said McIntyre.
When utilizing research-based diagnostic criteria, 4 times as many cases were identified.
Using DSM-5 with criteria, all patients identified as DMX will have DMX, however, only 5.1% of individuals who have DMX will be identified, and about 95% are at risk of receiving inappropriate treatment. Following criteria by psychiatrist Franco Benazzi, MD, PhD, approximately 10% of patients who are identified as having DMX will not actually have DMX, but less than 50% are at risk of receiving inappropriate treatment.
There is a question of which will be more detrimental, McIntire said; misdiagnosing someone who is “pure unipolar” as DMX or treating unidentified DMX with antidepressants?
The consequences of misdiagnosis/inappropriate treatment include: years (often a decade or more) of unnecessary suffering; treatment resistance; reduced likelihood of responding to eventual appropriate mood stabilizer treatment; treatment-emergent activation syndrome; and suicidality.
There are several tools that can be used to assess DMX, said McIntyre.
“The inappropriate overprescribing of antidepressants may contribute to drug-induced (hypo)manic episodes, treatment resistance, suicidality, and overall poor quality of life for many patients suffering from depression,” concluded McIntyre. “You will not know if a depressed person has (hypo)manic symptoms or a positive family history of bipolar disorder unless you ask every patient, every time.”
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More